These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 14514611

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ezetimibe: a turbocharger for the race to reach NCEP LDL goals.
    Lee S.
    S D J Med; 2005 Oct; 58(10):435-6. PubMed ID: 16425945
    [No Abstract] [Full Text] [Related]

  • 3. Liptruzet: a combination of ezetimibe and atorvastatin.
    Med Lett Drugs Ther; 2013 Jun 24; 55(1419):49-50. PubMed ID: 23797796
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
    Kastelein JJ, Sankatsing RR.
    Int J Clin Pract; 2005 Dec 24; 59(12):1464-71. PubMed ID: 16351680
    [Abstract] [Full Text] [Related]

  • 7. PTU induction provide quick screening of hypo and hyperlipidemia.
    Attitalla IH.
    Pak J Biol Sci; 2011 Dec 15; 14(24):1132-3. PubMed ID: 22335056
    [No Abstract] [Full Text] [Related]

  • 8. The need for a different cholesterol lowering drug.
    Steiner G.
    Can J Clin Pharmacol; 2003 Dec 15; 10 Suppl A():4A-6A. PubMed ID: 14571300
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A retrospective analysis of ezetimibe treatment in renal transplant recipients.
    Buchanan C, Smith L, Corbett J, Nelson E, Shihab F.
    Am J Transplant; 2006 Apr 15; 6(4):770-4. PubMed ID: 16539634
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of ezetimibe and low-dose simvastatin as primary treatment for dyslipidemia in peritoneal dialysis patients.
    Suzuki H, Inoue T, Watanabe Y, Kikuta T, Sato T, Tsuda M.
    Adv Perit Dial; 2010 Apr 15; 26():53-7. PubMed ID: 21348380
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe.
    Wang J, Williams CM, Hegele RA.
    Clin Genet; 2005 Feb 15; 67(2):175-7. PubMed ID: 15679830
    [Abstract] [Full Text] [Related]

  • 19. The ENHANCE study and marketing ezetimibe.
    Akdim F, Kastelein JJ, Gaudet D.
    JAMA; 2008 Jun 18; 299(23):2747; author reply 2747-8. PubMed ID: 18560001
    [No Abstract] [Full Text] [Related]

  • 20. [How sure is the combined lipid lowering?].
    Schäfer J.
    MMW Fortschr Med; 2005 Jan 13; 147(1-2):56. PubMed ID: 15704576
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.